Reversible leucopenia related to olanzapine

Movement Disorders

Volumn 14, Issue 5, 1999, Pages 872-873

  Meissner, Wassilios ^a   Schmidt, Tamara ^a   Kupsch, Andreas ^a   Trottenberg, Thomas ^a   Lempert, Thomas ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; LEVODOPA; OLANZAPINE; PERGOLIDE;

ADULT; AGRANULOCYTOSIS; CASE REPORT; FEMALE; HUMAN; LEUKOPENIA; MALE; NOTE; PARKINSONISM; PRIORITY JOURNAL;

BENZODIAZEPINES; FEMALE; HUMANS; LEUKOPENIA; MALE; MIDDLE AGED; PIRENZEPINE; PSYCHOTIC DISORDERS; SEROTONIN UPTAKE INHIBITORS;

EID: 0032711820     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/1531-8257(199909)14:5<872::AID-MDS1026>3.0.CO;2-Y     Document Type: Note

References (6)

1. Wolters EC, Jansen EN, Tuynman-Qua HG, Bergmans PL. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology 1996;47:1085-1087.
2. Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med 1993;329:204-205.
3. Beasley CM, Tollefson GD, Tran PV. Safety of olanzapine. J Clin Psychiatry 1997;58(suppl 10):13-17.
4. Flynn SW, Altman S, McEwan GW, Black LL, Greenidge LL, Honer WG. Prolongation of clozapine-induced granulocytopenia associated with olanzapine. J Clin Psychopharmacol 1997;17:494-495.
5. Tollefson GD, Beasley CM Jr, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997;154:457-465.
6. Finkel B, Lerner A, Oyffe I, Rudinski D, Sigal M, Weizman A. Olanzapine treatment in patients with typical and atypical neuroleptic-associated agranulocytosis. Int Clin Psychopharmacol 1998; 13:133-135.